In my view, the most pressure on the share price has been caused by management issuing a tremendous number of stock and warrants.
Granted that the present market cap of 250 million of a phase 3 biotech in cancer of a rare condition at the verge of TLD is too low by about 200-250 million... However holding back new investors is the following in my view: listed at OTC, a staggering 400 million in news shares waiting to come to the market, and a bad reputation of overpromising underdelivering.
This can all be forgiven very soon and very fast by mister market.
Market Data 
Markets 
AI
